Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products

Published: Thursday, April 12, 2012
Last Updated: Wednesday, April 11, 2012
Bookmark and Share
Ramcon covers the Northern European countries and serves customers in Denmark, Sweden, Norway, Finland and Iceland with a highly specialized sales force.

Since February of this year Danish Ramcon A/S offers Anagnostics’ drugs of abuse testing and pharmacogenetics solutions as distribution partner.

During the course of the year, further products, especially relating to severe infection testing will follow.

Establishing the innovative products in the Northern European Countries as well as competent and first class customer support are common goals of the partners.

“The decision to partner with Ramcon simply made sense, since Ramcon already specializes in tests and systems for in vitro diagnostics and life sciences with a loyal and broad customer base. Ramcon focuses on first class end-user service and support. Therefore both organizations perfectly fit together”, summarizes Markus Jaquemar, CMO Anagnostics Bioanalysis GmbH.

Jesper Hardt, CEO of Ramcon A/S, is looking forward to a successful partnership: “We can see a clear trend towards multiplex testing. Anagnostics perfectly responds to these market needs with the hyborg system and its testing menu. The fast and efficient response to actual drug consumption will secure access to drug therapy institutions. The efficient and highly sensitive pharmacogenetics test will benefit small or mid-sized pathological entities.”

Multiplex Diagnostics with Focus on Drugs of Abuse Screening, Pharmacogenetics (Oncology) and Serve Infection Testing Anagnostics Bioanalysis with its headquarters in St. Valentin (Austria) is specialized in developing systems, devices and tests in drugs of abuse screening, pharmacogenetics (oncology) and tests for diagnosing severe infections.

With the unique ability to perform protein as well as DNA based assays the hyborg system offers a testing platform meeting needs of personalized medicine and integrated diagnostics.

Anagnostics was established in 2005 by Bernhard Ronacher, a molecular genetics scientist. A cylindrical microarray - the hybcell - is the core of the patented multiplex technology.

Combined with the hyborg analysis system multi-parameter assays are performed in a fully automated manner.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Anagnostics Enters Sales Cooperation with Analis S.A.
Company enters cooperation for Belgium and Luxembourg.
Monday, December 10, 2012
Scientific News
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!